MorphoSys offers $1.7bn for Constellation, but investors see starsShares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to Share XMorphoSys offers $1.7bn for Constellation, but investors see starshttps://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/
Rubius launches $200m IPO to fund red blood cell therapiesRubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel Share XRubius launches $200m IPO to fund red blood cell therapieshttps://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/
Catamaran joins the CAR-NK fleet, raising $42m in first roundCatamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its Share XCatamaran joins the CAR-NK fleet, raising $42m in first roundhttps://pharmaphorum.com/news/catamaran-joins-the-car-nk-fleet-raising-42m-in-first-round/
ADC Therapeutics sets terms for $125m IPOSwiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop Share XADC Therapeutics sets terms for $125m IPOhttps://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/
